Emostasi e Trombosi, S.I. di (2026) “PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY: P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators”, Bleeding, Thrombosis and Vascular Biology, 5(s1). doi:10.4081/btvb.2026.536.